药明康德(603259) - 2025 Q2 - 季度业绩预告

Performance Overview and Key Highlights The company forecasts strong semi-annual growth in revenue, net profit, and adjusted net profit, driven by core CRDMO business and one-time investment gains 2025 Semi-Annual Performance Forecast Key Metrics (vs. Prior Year) | Metric | 2025 Semi-Annual (Forecast) | 2024 Semi-Annual (Actual) | YoY Growth | | :--- | :--- | :--- | :--- | | Operating Revenue | approx. 20.799 billion yuan | 17.241 billion yuan | approx. 20.64% | | Net Profit Attributable to Shareholders | approx. 8.561 billion yuan | 4.240 billion yuan | approx. 101.92% | | Adjusted Net Profit Attributable to Shareholders | approx. 6.315 billion yuan | 4.372 billion yuan | approx. 44.43% | | Non-IFRS Net Profit Attributable to Shareholders | approx. 5.582 billion yuan | 4.414 billion yuan | approx. 26.47% | | Basic Earnings Per Share | approx. 3.01 yuan/share | 1.46 yuan/share | approx. 106.16% | - The core of the company's growth lies in its unique “integrated, end-to-end” CRDMO business model, continuously expanding new capabilities and capacities, optimizing efficiency, and meeting client demands[3][12] 2025 Semi-Annual Performance Forecast Details Detailed forecasts for H1 2025 show continuing operations revenue outperforming overall growth, with adjusted net profit growth significantly higher than non-IFRS due to exchange rate impacts 2025 Semi-Annual Performance Forecast Detailed Data | Financial Metric | Forecast Amount (RMB) | YoY Growth Rate | | :--- | :--- | :--- | | Operating Revenue | approx. 20.799 billion yuan | approx. 20.64% | | Revenue from Continuing Operations | Not applicable | approx. 24.24% | | Adjusted Net Profit Attributable to Shareholders | approx. 6.315 billion yuan | approx. 44.43% | | Non-IFRS Net Profit Attributable to Shareholders | approx. 5.582 billion yuan | approx. 26.47% | | Net Profit Attributable to Shareholders | approx. 8.561 billion yuan | approx. 101.92% | | Total Profit | approx. 9.907 billion yuan | approx. 96.20% | | Basic Earnings Per Share | approx. 3.01 yuan/share | approx. 106.16% | 2024 Semi-Annual Performance Review (Comparison Baseline) The report provides 2024 prior period financial data as a comparison baseline for assessing 2025 H1 performance growth 2024 Semi-Annual Performance Data | Financial Metric | Amount (RMB) | | :--- | :--- | | Operating Revenue | 17.241 billion yuan | | Adjusted Net Profit Attributable to Shareholders | 4.372 billion yuan | | Non-IFRS Net Profit Attributable to Shareholders | 4.414 billion yuan | | Net Profit Attributable to Shareholders | 4.240 billion yuan | | Total Profit | 5.050 billion yuan | | Basic Earnings Per Share | 1.46 yuan/share | Analysis of Performance Growth Drivers Significant performance growth is driven by robust core business expansion and non-operating gains from associate equity sales Principal Business Growth The company's principal business growth is driven by its integrated CRDMO model, new investments, and optimized operational efficiency - The fundamental driver of performance growth stems from the company's focus on and deepening of its CRDMO business model, meeting strong client demand for R&D and manufacturing outsourcing[12] Impact of Non-Operating Gains and Losses Non-operating gains significantly boosted profit, mainly from selling WuXi XDC Cayman Inc. equity, yielding approximately 3.21 billion RMB - The primary contribution to non-recurring gains and losses in this period comes from the sale of partial equity in WuXi XDC Cayman Inc., with an estimated gain of approximately 3.21 billion yuan[13] Risk Warning and Other Matters The company states no major uncertainties affect the forecast, reminding investors that disclosed data are preliminary and unaudited, pending the official semi-annual report - The performance forecast data are preliminary and have not been audited or reviewed by a certified public accountant[8][14] - The company advises investors to be aware of investment risks, as final financial data will be based on the officially disclosed semi-annual report[15]